Other

After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI

Medtronic After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI decreased by 7.4% to -$116.00M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2020 to FY 2025), After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI shows an upward trend with a -5.8% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ2 2015
Last reportedQ1 2026
Metric ID: other_unrealized_gain_loss_on_interest_rate_cash_flow_he_7f22f9

Historical Data

12 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '25Q3 '25Q4 '25Q1 '26
Value-$253.00M-$79.00M$16.00M$116.00M$474.00M$694.00M$852.00M$92.00M-$149.00M-$276.00M-$108.00M-$116.00M
QoQ Change—+68.8%+120.3%+625.0%+308.6%+46.4%+22.8%-89.2%-262.0%-85.2%+60.9%-7.4%
YoY Change————+287.4%+978.5%>999%-20.7%————
Range-$276.00M – $852.00M
CAGR-24.7%
Avg YoY Growth>999%
Median YoY Growth+632.9%

Frequently Asked Questions

What is Medtronic's after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in aoci?
Medtronic (MDT) reported after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in aoci of -$116.00M in Q1 2026.
What is the long-term trend for Medtronic's after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in aoci?
Over 3 years (2020 to 2025), Medtronic's after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in aoci has grown at a -5.8% compound annual growth rate (CAGR), from -$129.00M to -$108.00M.